SYMPLIFY – Observational study to assess a multi-cancer early detection test in individuals referred with signs and symptoms of cancer

niversity of Oxford0 个研究点目标入组 6,238 人开始时间: 2021年8月13日最近更新: 2023年7月10日

适应症

试验速览

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37352875/ (added 26/06/2023)

•1. Participants referred to an RDC or relevant 2WW pathway to rule a cancer diagnosis in or out will be invited to participate in the study.
•2. Willing and able to give informed consent for participation in the study.
•3. Male or Female, aged 18 years or above.
•4. Referred to a RDC or a gynae, lung, upper GI or lower GI cancer 2WW pathway.

•1. Has a history of invasive or haematological malignancy diagnosed within the previous 3 years.
•2. Has undergone definitive treatment for invasive or haematological malignancy in the last 3 years (adjuvant hormone therapy is permissible in this context).
•3. Is taking cytotoxic or demethylating agents such as methotrexate.
•4. Previous or current participation in another GRAIL study. Participation” is defined as having signed consent and provided a blood sample.

发起方